A phase II evaluation of mifepristone in the treatment of recurrent or persistent epithelial ovarian, fallopian or primary peritoneal cancer: A gynecologic oncology group study
Authors:
- Thomas F. RoceretoTRThomas F. Rocereto
- Laurie SmallLSLaurie Small
- 1 March 2010
- journal article
- research article
- Published by Elsevier in Gynecologic Oncology
- Vol. 116 (3) , 332-334
Abstract
No abstract availableKeywords
This publication has 6 references indexed in Scilit:
- Intraperitoneal Cisplatin and Paclitaxel in Ovarian CancerNew England Journal of Medicine, 2006
- Phase II Study of Mifepristone (RU486) in Refractory Ovarian CancerGynecologic Oncology, 2000
- New Guidelines to Evaluate the Response to Treatment in Solid TumorsJNCI: Journal of the National Cancer Institute, 2000
- Cyclophosphamide and Cisplatin Compared with Paclitaxel and Cisplatin in Patients with Stage III and Stage IV Ovarian CancerNew England Journal of Medicine, 1996
- Endocrine Factors in Common Epithelial Ovarian Cancer*Endocrine Reviews, 1991
- THE USE OF CONFIDENCE OR FIDUCIAL LIMITS ILLUSTRATED IN THE CASE OF THE BINOMIALBiometrika, 1934